LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Search

Minerva Neurosciences Inc

Ouvert

2.11 1.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.03

Max

2.2

Chiffres clés

By Trading Economics

P/E

Moyenne du Secteur

1.444

35.293

BPA

-0.43

Employés

8

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

4M

14M

Ouverture précédente

0.67

Clôture précédente

2.11

Minerva Neurosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2025, 23:01 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Résultats

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Résultats

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Acquisitions, Fusions, Rachats

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Acquisitions, Fusions, Rachats

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Résultats

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Résultats

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Résultats

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparaison

Variation de prix

Minerva Neurosciences Inc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

$

À Propos Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
help-icon Live chat